NASDAQ:BXRX

Baudax Bio Competitors

$1.08
+0.02 (+1.89 %)
(As of 04/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.02
Now: $1.08
$1.10
50-Day Range
$1.01
MA: $1.28
$1.57
52-Week Range
$0.97
Now: $1.08
$4.95
Volume1.11 million shs
Average Volume5.16 million shs
Market Capitalization$75.75 million
P/E RatioN/A
Dividend YieldN/A
Beta2.56

Competitors

Baudax Bio (NASDAQ:BXRX) Vs. FMS, DVA, SHC, PGNY, TVTY, and OTRK

Should you be buying BXRX stock or one of its competitors? Companies in the industry of "miscellaneous health & allied services, not elsewhere classified" are considered alternatives and competitors to Baudax Bio, including Fresenius Medical Care AG & Co. KGaA (FMS), DaVita (DVA), Sotera Health (SHC), Progyny (PGNY), Tivity Health (TVTY), and Ontrak (OTRK).

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) and Baudax Bio (NASDAQ:BXRX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, risk, valuation and institutional ownership.

Insider and Institutional Ownership

1.6% of Fresenius Medical Care AG & Co. KGaA shares are owned by institutional investors. Comparatively, 7.9% of Baudax Bio shares are owned by institutional investors. 13.1% of Baudax Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Volatility & Risk

Fresenius Medical Care AG & Co. KGaA has a beta of 1.21, meaning that its share price is 21% more volatile than the S&P 500. Comparatively, Baudax Bio has a beta of 2.56, meaning that its share price is 156% more volatile than the S&P 500.

Earnings & Valuation

This table compares Fresenius Medical Care AG & Co. KGaA and Baudax Bio's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fresenius Medical Care AG & Co. KGaA$19.58 billion1.18$1.34 billion$2.5315.55
Baudax BioN/AN/A$-32,560,000.00($3.48)-0.31

Fresenius Medical Care AG & Co. KGaA has higher revenue and earnings than Baudax Bio. Baudax Bio is trading at a lower price-to-earnings ratio than Fresenius Medical Care AG & Co. KGaA, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and target prices for Fresenius Medical Care AG & Co. KGaA and Baudax Bio, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Fresenius Medical Care AG & Co. KGaA19702.35
Baudax Bio00203.00

Fresenius Medical Care AG & Co. KGaA presently has a consensus price target of $48.00, indicating a potential upside of 21.98%. Baudax Bio has a consensus price target of $13.50, indicating a potential upside of 1,150.00%. Given Baudax Bio's stronger consensus rating and higher probable upside, analysts plainly believe Baudax Bio is more favorable than Fresenius Medical Care AG & Co. KGaA.

Profitability

This table compares Fresenius Medical Care AG & Co. KGaA and Baudax Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Fresenius Medical Care AG & Co. KGaA7.38%10.62%4.15%
Baudax BioN/AN/AN/A

Summary

Fresenius Medical Care AG & Co. KGaA beats Baudax Bio on 8 of the 13 factors compared between the two stocks.

Baudax Bio (NASDAQ:BXRX) and DaVita (NYSE:DVA) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership and valuation.

Insider & Institutional Ownership

7.9% of Baudax Bio shares are held by institutional investors. Comparatively, 91.7% of DaVita shares are held by institutional investors. 13.1% of Baudax Bio shares are held by company insiders. Comparatively, 1.0% of DaVita shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Risk & Volatility

Baudax Bio has a beta of 2.56, indicating that its stock price is 156% more volatile than the S&P 500. Comparatively, DaVita has a beta of 1.3, indicating that its stock price is 30% more volatile than the S&P 500.

Earnings & Valuation

This table compares Baudax Bio and DaVita's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Baudax BioN/AN/A$-32,560,000.00($3.48)-0.31
DaVita$11.39 billion1.08$810.98 million$5.4020.82

DaVita has higher revenue and earnings than Baudax Bio. Baudax Bio is trading at a lower price-to-earnings ratio than DaVita, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations for Baudax Bio and DaVita, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Baudax Bio00203.00
DaVita12102.00

Baudax Bio currently has a consensus target price of $13.50, indicating a potential upside of 1,150.00%. DaVita has a consensus target price of $124.50, indicating a potential upside of 10.72%. Given Baudax Bio's stronger consensus rating and higher possible upside, equities research analysts clearly believe Baudax Bio is more favorable than DaVita.

Profitability

This table compares Baudax Bio and DaVita's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Baudax BioN/AN/AN/A
DaVita7.32%43.99%5.27%

Summary

DaVita beats Baudax Bio on 8 of the 13 factors compared between the two stocks.

Baudax Bio (NASDAQ:BXRX) and Sotera Health (NYSE:SHC) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership and valuation.

Insider & Institutional Ownership

7.9% of Baudax Bio shares are held by institutional investors. 13.1% of Baudax Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Baudax Bio and Sotera Health's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Baudax BioN/AN/A$-32,560,000.00($3.48)-0.31
Sotera HealthN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of recent recommendations for Baudax Bio and Sotera Health, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Baudax Bio00203.00
Sotera Health001003.00

Baudax Bio currently has a consensus target price of $13.50, indicating a potential upside of 1,150.00%. Sotera Health has a consensus target price of $32.75, indicating a potential upside of 31.32%. Given Baudax Bio's higher possible upside, equities research analysts clearly believe Baudax Bio is more favorable than Sotera Health.

Profitability

This table compares Baudax Bio and Sotera Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Baudax BioN/AN/AN/A
Sotera HealthN/AN/AN/A

Summary

Baudax Bio beats Sotera Health on 3 of the 4 factors compared between the two stocks.

Progyny (NASDAQ:PGNY) and Baudax Bio (NASDAQ:BXRX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, valuation, profitability, earnings and institutional ownership.

Profitability

This table compares Progyny and Baudax Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Progyny1.03%7.43%5.04%
Baudax BioN/AN/AN/A

Analyst Recommendations

This is a summary of recent ratings for Progyny and Baudax Bio, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Progyny00603.00
Baudax Bio00203.00

Progyny presently has a consensus price target of $38.8333, indicating a potential downside of 23.93%. Baudax Bio has a consensus price target of $13.50, indicating a potential upside of 1,150.00%. Given Baudax Bio's higher possible upside, analysts plainly believe Baudax Bio is more favorable than Progyny.

Volatility & Risk

Progyny has a beta of 1.83, indicating that its share price is 83% more volatile than the S&P 500. Comparatively, Baudax Bio has a beta of 2.56, indicating that its share price is 156% more volatile than the S&P 500.

Insider and Institutional Ownership

58.5% of Progyny shares are held by institutional investors. Comparatively, 7.9% of Baudax Bio shares are held by institutional investors. 33.3% of Progyny shares are held by company insiders. Comparatively, 13.1% of Baudax Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Progyny and Baudax Bio's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Progyny$229.68 million19.39$-8,570,000.00$0.11464.09
Baudax BioN/AN/A$-32,560,000.00($3.48)-0.31

Progyny has higher revenue and earnings than Baudax Bio. Baudax Bio is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks.

Summary

Progyny beats Baudax Bio on 10 of the 12 factors compared between the two stocks.

Tivity Health (NASDAQ:TVTY) and Baudax Bio (NASDAQ:BXRX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, valuation, profitability, earnings and institutional ownership.

Profitability

This table compares Tivity Health and Baudax Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Tivity Health-47.44%128.43%6.11%
Baudax BioN/AN/AN/A

Analyst Recommendations

This is a summary of recent ratings for Tivity Health and Baudax Bio, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Tivity Health12502.50
Baudax Bio00203.00

Tivity Health presently has a consensus price target of $22.1250, indicating a potential downside of 7.81%. Baudax Bio has a consensus price target of $13.50, indicating a potential upside of 1,150.00%. Given Baudax Bio's stronger consensus rating and higher possible upside, analysts plainly believe Baudax Bio is more favorable than Tivity Health.

Volatility & Risk

Tivity Health has a beta of 2.49, indicating that its share price is 149% more volatile than the S&P 500. Comparatively, Baudax Bio has a beta of 2.56, indicating that its share price is 156% more volatile than the S&P 500.

Insider and Institutional Ownership

91.6% of Tivity Health shares are held by institutional investors. Comparatively, 7.9% of Baudax Bio shares are held by institutional investors. 11.8% of Tivity Health shares are held by company insiders. Comparatively, 13.1% of Baudax Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Tivity Health and Baudax Bio's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tivity Health$1.13 billion1.04$-286,820,000.00$2.0211.88
Baudax BioN/AN/A$-32,560,000.00($3.48)-0.31

Baudax Bio has lower revenue, but higher earnings than Tivity Health. Baudax Bio is trading at a lower price-to-earnings ratio than Tivity Health, indicating that it is currently the more affordable of the two stocks.

Summary

Baudax Bio beats Tivity Health on 7 of the 13 factors compared between the two stocks.

Ontrak (NASDAQ:OTRK) and Baudax Bio (NASDAQ:BXRX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.

Valuation and Earnings

This table compares Ontrak and Baudax Bio's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ontrak$35.10 million16.31$-25,660,000.00($1.15)-28.15
Baudax BioN/AN/A$-32,560,000.00($3.48)-0.31

Ontrak has higher revenue and earnings than Baudax Bio. Ontrak is trading at a lower price-to-earnings ratio than Baudax Bio, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Ontrak and Baudax Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ontrak-43.10%N/A-58.54%
Baudax BioN/AN/AN/A

Risk and Volatility

Ontrak has a beta of 2.52, indicating that its stock price is 152% more volatile than the S&P 500. Comparatively, Baudax Bio has a beta of 2.56, indicating that its stock price is 156% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for Ontrak and Baudax Bio, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ontrak02302.60
Baudax Bio00203.00

Ontrak presently has a consensus price target of $47.20, indicating a potential upside of 45.81%. Baudax Bio has a consensus price target of $13.50, indicating a potential upside of 1,150.00%. Given Baudax Bio's stronger consensus rating and higher possible upside, analysts clearly believe Baudax Bio is more favorable than Ontrak.

Insider & Institutional Ownership

27.5% of Ontrak shares are held by institutional investors. Comparatively, 7.9% of Baudax Bio shares are held by institutional investors. 58.2% of Ontrak shares are held by company insiders. Comparatively, 13.1% of Baudax Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.


Baudax Bio Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Fresenius Medical Care AG & Co. KGaA logo
FMS
Fresenius Medical Care AG & Co. KGaA
1.7$39.35+0.4%$23.05 billion$19.58 billion15.62
DaVita logo
DVA
DaVita
1.9$112.45+1.0%$12.30 billion$11.39 billion16.86
Sotera Health logo
SHC
Sotera Health
2.0$24.94+1.4%$7.05 billionN/A0.00Analyst Upgrade
News Coverage
Progyny logo
PGNY
Progyny
1.5$51.05+1.2%$4.45 billion$229.68 million464.09Insider Selling
Tivity Health logo
TVTY
Tivity Health
1.0$24.00+0.9%$1.18 billion$1.13 billion-2.17
Ontrak logo
OTRK
Ontrak
1.7$32.37+5.2%$572.63 million$35.10 million-19.04
SOC Telemed logo
TLMD
SOC Telemed
1.6$7.00+5.0%$537.41 millionN/A0.00
Viemed Healthcare logo
VMD
Viemed Healthcare
1.1$9.42+0.8%$369.12 million$80.26 million13.08
Caladrius Biosciences logo
CLBS
Caladrius Biosciences
1.5$1.62+3.7%$96.39 millionN/A-2.53Decrease in Short Interest
GRNV
GreenVision Acquisition
0.3$10.19+0.4%$73.25 millionN/A0.00
This page was last updated on 4/22/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.